1. Ikemura N, Taminishi S, Inaba T, Arimori T, Motooka D, Katoh K, Kirita Y, Higuchi Y, Li S, Suzuki T, Itoh Y, Ozaki Y, Nakamura S, Matoba S, Standley DM*, Okamoto T*, Takagi J*, Hoshino A*. An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo. Sci Transl Med. 2022 Apr 26;eabn7737. DOI: 10.1126/scitranslmed.abn7737
2. 星野 温,有森 貴夫,”指向性進化法による高親和性ACE2創出とCOVID-19創薬展開” 医学のあゆみ, 278(6),588-595 (2021)
3. 星野温, 創薬研究者がこれだけは知っておきたい最新のウイルス学 第10章第10節 ウイルスと強力に結合して重症化を防ぐタンパク質(ACE2) 技術情報協会 2021年8月発刊
4. Sano E, Suzuki T, Hashimoto R, Itoh Y, Sakamoto A, Sakai Y, Saito A, Okuzaki D, Motooka D, Muramoto Y, Noda T, Takasaki D, Sakuragi JI, Minami S, Kobayashi T, Yamamoto T, Matsumura Y, Nagao M, Okamoto T (corresponding author), Takayama K. Cell response analysis in SARS-CoV-2 infected bronchial organoids. Commun Biol. (accepted in principle)
5. Miyamoto Y, Itoh Y, Suzuki T, Tanaka T, Sakai Y, Koido M, Hata C, Wang CX, Otani M, Moriishi K, Tachibana T, Kamatani Y, Yoneda Y, Okamoto T (corresponding author), Oka M. SARS-CoV-2 ORF6 disrupts nucleocytoplasmic trafficking to advance viral replication. Commun Biol. (In press)
6. Tanaka T, Saito A, Suzuki T, Miyamoto Y, Takayama K, Okamoto T, Moriishi K. Establishment of a stable SARS-CoV-2 replicon system for application in high-throughput screening. Antiviral Res. 2022 Mar;199:105268.
7. Tsuji S, Minami S, Hashimoto R, Konishi Y, Suzuki T, Kondo T, Sasai M, Torii S, Ono C, Shichinohe S, Sato S, Wakita M, Okumura S, Nakano S, Matsudaira T, Matsumoto T, Kawamoto S, Yamamoto M, Watanabe T, Matsuura Y, Takayama K, Kobayashi T, Okamoto T, Hara E. SARS-CoV-2 infection triggers paracrine senescence and leads to a sustained senescence-associated inflammatory response. Nat Aging. 2022 Jan 25;2:115-124
8. Meng B#, Abdullahi A#, Ferreira IATM#, Goonawardane N#, Saito A#, Kimura I#, Yamasoba D#, Gerber PP, Fatihi S, Rathore S, Zepeda SK, Papa G, Kemp SA, Ikeda T, Toyoda M, Tan TS, Kuramochi J, Mitsunaga S, Ueno T, Shirakawa K, Takaori-Kondo A, Brevini T, Mallery DL, Charles OJ; CITIID-NIHR BioResource COVID-19 Collaboration; Genotype to Phenotype Japan (G2P-Japan) Consortium; Ecuador-COVID19 Consortium, Bowen JE, Joshi A, Walls AC, Jackson L, Martin D, Smith KGC, Bradley J, Briggs JAG, Choi J, Madissoon E, Meyer KB, Mlcochova P, Ceron-Gutierrez L, Doffinger R, Teichmann SA, Fisher AJ, Pizzuto MS, de Marco A, Corti D, Hosmillo M, Lee JH, James LC, Thukral L, Veesler D, Sigal A, Sampaziotis F, Goodfellow IG, Matheson NJ, Sato K, Gupta RK. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature. 2022 Mar;603(7902):706-714.
9. 鈴木達也、齊藤暁, RNAウイルスの新規リバースジェネティクス法とその応用.日本薬理学雑誌, 157(2) 134-138 2022年
10. Kimura I, Kosugi Y, Wu J, Zahradnik J, Yamasoba D, Butlertanaka EP, Tanaka YL, Uriu K, Liu Y, Morizako N, Shirakawa K, Kazuma Y, Nomura R, Horisawa Y, Tokunaga K, Ueno T, Takaori-Kondo A, Schreiber G, Arase H; Genotype to Phenotype Japan (G2P-Japan) Consortium, Motozono C, Saito A, Nakagawa S, Sato K. The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance. Cell Rep. 2022 Jan 11;38(2):110218.